OCUTF (Ocumension Therapeutics) ROCE %: -1.32% (As of Dec. 2025)


OCUTF Ocumension Therapeutics OCUTF
52 GF Score
Price $0.70
GF Value $2.82
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Ocumension Therapeutics ROCE %?

Ocumension Therapeutics OCUTF 52 ROCE % is -1.32% as of Dec. 2025. GuruFocus rates OCUTF with a GF Score™ of 52/100 and a GF Value™ of $2.82 (Possible Value Trap). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ocumension Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2025 was -1.32%.

Ocumension Therapeutics  (OTCPK:OCUTF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Ocumension Therapeutics ROCE % Related Terms

Ocumension Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Ocumension Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocumension Therapeutics ROCE % Chart

Ocumension Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -9.34 -12.91 -13.00 -7.76 -4.15

Ocumension Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.89 -10.29 -6.99 -6.99 -1.32
OCUTF
52GF Score
Ocumension Therapeutics OCUTF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ocumension Therapeutics ROCE % Calculation

Ocumension Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-22.153/( ( (545.8 - 21.289) + (580.837 - 36.455) )/ 2 )
=-22.153/( (524.511+544.382)/ 2 )
=-22.153/534.4465
=-4.15 %

Ocumension Therapeutics's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-7.048/( ( (542.718 - 21.54) + (580.837 - 36.455) )/ 2 )
=-7.048/( ( 521.178 + 544.382 )/ 2 )
=-7.048/532.78
=-1.32 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -1.32% mean?
Ocumension Therapeutics (OCUTF) has a ROCE % of -1.32% as of Dec. 2025.
Is Ocumension Therapeutics' ROCE % too high?
Ocumension Therapeutics' current ROCE % is -1.32%. Overall, Ocumension Therapeutics has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ocumension Therapeutics' ROCE % compare to VRTX and REGN?
Ocumension Therapeutics' ROCE % of -1.32% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Ocumension Therapeutics's current ROCE % is -1.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocumension Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ocumension Therapeutics (OCUTF) is currently considered Possible Value Trap. The stock's GF Value™ is $2.82, compared to a current price of $0.70 — trading 75.2% below its estimated fair value. The current ROCE % is -1.32%. Ocumension Therapeutics' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Ocumension Therapeutics (OCUTF), the current ROCE % is -1.32% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ocumension Therapeutics (OCUTF) Overvalued in 2026?

Based on GuruFocus' analysis, Ocumension Therapeutics stock appears to be undervalued. The current stock price of $0.70 is trading 75.2% below its estimated GF Value™ of $2.82. GuruFocus considers Ocumension Therapeutics to be Possible Value Trap.

Key valuation signals for OCUTF:

  • ROCE %: -1.32%
  • GF Value™: $2.82 vs. price of $0.70 (75.2% below fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the OCUTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ocumension Therapeutics Business Description

Other Exchanges 01477:Hong Kong5DG:Germany
Address No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
52GF Score

Get the complete analysis for OCUTF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.70
Price
$2.82
GF Value